Your Health, We Care
Another Name琥珀酸莫博赛替尼胶囊，安卫力，Exkivity，TAK-788，LuciMob
IndicationsIt is used for the treatment of non-small cell lung cancer caused by a specific gene mutation — insertion mutation in exon 20 of the epidermal growth factor receptor (EGFR).
Reg No.07 L 0993/23
Inspection NO.1782-23
Mobocertinib is a prescription drug. It received accelerated approval from the U.S. Food and Drug Administration (FDA) on September 15, 2021, targeting epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Use it strictly as directed by a doctor.
Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation
Route and frequency of administration for Mobocertinib: Oral, once daily.
The dosage of Mobocertinib should be adjusted according to the patient’s actual condition. Please consult a doctor and strictly follow medical advice.
Recommended reading: Dosage and Administration of Mobocertinib
Common adverse reactions: Diarrhea, rash, stomatitis, etc.
Serious adverse reactions: QTc prolongation, ILD/pneumonitis, etc.
Reference article: Adverse Reactions of Mobocertinib
Pregnancy: If you become pregnant or suspect you may be pregnant during treatment, inform your doctor immediately.
Lactation: If you are breastfeeding or planning to breastfeed, inform your doctor. It is not known whether Mobocertinib is excreted in human milk. Do not breastfeed during treatment with Mobocertinib and for 1 week after the last dose.
1. Take Mobocertinib strictly as prescribed by your doctor.
2. Mobocertinib may be taken with or without food.
3. Swallow Mobocertinib capsules whole. Do not open, chew, or dissolve the capsule contents.
from FDA，2023.09
